Ocular Myasthenia Gravis Treatment: The Case Against Prednisone Therapy and Thymectomy
Arch Neurol 64:1790-1792,1794, Gilbert,M.E.,et al, 2007
Pyridostigmine-Induced Microcephaly
Neurol 54:1873-1874, Niesen,C.E.&Shah,N.S., 2000
Self-Reported Exposure to Neurotoxic Chemical Combinations in the Gulf War:A Cross-Sectional Epidemiologic Study
JAMA 227:231-237, 2591997., Haley,R.W.&Kurt,T.L., 1997
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Pyridostigmine Used as a Nerve Agent Pretreatment Under Wartime Conditions
JAMA 266:693-695, Keeler,J.R.,et al, 1991
A Child with Arthrogryposis
Neurol 91:e995-e998, Irumudomom, O. & Ghosh, P.S., 2018
International Consensus Guidance for Management of Myasthenia Gravis
Neurol 87:419-425, Sanders, D.B.,et al, 2016
Therapy for Nerve Agent Poisoning
Arch Neurol 61:649-652, Newmark,J., 2004
Management of Myasthenia Gravis
Semin Neurol 24:41-48, Saperstein,D.S. &Barohn,R.J., 2004
Myasthenia Gravis
NEJM 330:1797-1810, Drachman,D.B., 1994
Nerve Agents:A Review
Neurol 42:946-950, Gunderson,C.H.,et al, 1992
Management of Injuries Due to Chemical Weapons
BMJ 302:129-130, Murray,V.S.G.&Volans,G.N., 1991
Controversies About the Treatment of Myasthenia Gravis
JNNP 43:644-659, Rowland,L.P., 1980